{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:22:01Z","timestamp":1792714921639,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10875-022-01222-8","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T03:02:53Z","timestamp":1647226973000},"page":"811-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Health-Related Quality of Life in 91 Patients with X-Linked Agammaglobulinemia"],"prefix":"10.1007","volume":"42","author":[{"given":"Katherine","family":"Altman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Hernandez-Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Scalchunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"de la Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"2","key":"1222_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279\u201390.","journal-title":"Cell"},{"issue":"6409","key":"1222_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226\u201333.","journal-title":"Nature"},{"issue":"6","key":"1222_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/ACI.0000000000000584","volume":"19","author":"BMJ Shillitoe","year":"2019","unstructured":"Shillitoe BMJ, Gennery AR. An update on X-Linked agammaglobulinaemia: clinical manifestations and management. Curr Opin Allergy Clin Immunol. 2019;19(6):571\u20137.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"1222_CR4","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.waojou.2019.100018","volume":"12","author":"ZA El-Sayed","year":"2019","unstructured":"El-Sayed ZA, et al. X-linked agammaglobulinemia (XLA):phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12(3):100018.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0241-1","volume":"36","author":"MN Similuk","year":"2016","unstructured":"Similuk MN, et al. Life with a primary immune deficiency: a systematic synthesis of the literature and proposed research agenda. J Clin Immunol. 2016;36(2):123\u201333.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1222_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10875-013-9942-x","volume":"34","author":"JR Hurst","year":"2014","unstructured":"Hurst JR, et al. Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes. J Clin Immunol. 2014;34(1):68\u201375.","journal-title":"J Clin Immunol"},{"issue":"2\u20133","key":"1222_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clim.2005.11.002","volume":"118","author":"V Howard","year":"2006","unstructured":"Howard V, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol. 2006;118(2\u20133):201\u20138.","journal-title":"Clin Immunol"},{"issue":"5","key":"1222_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/MD.0b013e318187ed81","volume":"87","author":"JA Winkelstein","year":"2008","unstructured":"Winkelstein JA, et al. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore). 2008;87(5):253\u20138.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1222_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10875-008-9270-8","volume":"29","author":"A Soresina","year":"2009","unstructured":"Soresina A, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29(4):501\u20137.","journal-title":"J Clin Immunol"},{"key":"1222_CR10","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna 2021. https:\/\/www.R-project.org\/."},{"issue":"4","key":"1222_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1067\/mpd.2002.127711","volume":"141","author":"ME Conley","year":"2002","unstructured":"Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr. 2002;141(4):566\u201371.","journal-title":"J Pediatr"},{"issue":"2","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1081-1206(10)61469-X","volume":"93","author":"H Tcheurekdjian","year":"2004","unstructured":"Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol. 2004;93(2):160\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10875-017-0404-8","volume":"37","author":"NL Rider","year":"2017","unstructured":"Rider NL, et al. Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment. J Clin Immunol. 2017;37(5):461\u201375.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1222_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/cei.13210","volume":"194","author":"J Hajjar","year":"2018","unstructured":"Hajjar J, et al. Fatigue and the wear-off effect in adult patients with common variable immunodeficiency. Clin Exp Immunol. 2018;194(3):327\u201338.","journal-title":"Clin Exp Immunol"},{"issue":"13","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1212\/WNL.0b013e3181f4d80d","volume":"75","author":"P Grossman","year":"2010","unstructured":"Grossman P, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;75(13):1141\u20139.","journal-title":"Neurology"},{"issue":"9","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","volume":"103","author":"M Berger","year":"2010","unstructured":"Berger M, et al. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856\u201363.","journal-title":"South Med J"},{"issue":"2","key":"1222_CR17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1200\/JOP.2017.027136","volume":"14","author":"J Park","year":"2018","unstructured":"Park J, Look KA. Relationship between objective financial burden and the health-related quality of life and mental health of patients with cancer. J Oncol Pract. 2018;14(2):e113\u201321.","journal-title":"J Oncol Pract"},{"issue":"7","key":"1222_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10875-014-0072-x","volume":"34","author":"P Titman","year":"2014","unstructured":"Titman P, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(7):844\u201352.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1222_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s10875-016-0284-3","volume":"36","author":"BA Bryan","year":"2016","unstructured":"Bryan BA, et al. Respiratory health and related quality of life in patients with congenital agammaglobulinemia in the northern region of the UK. J Clin Immunol. 2016;36(5):472\u20139.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1222_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jaip.2019.02.013","volume":"7","author":"D Peshko","year":"2019","unstructured":"Peshko D, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(6):1929-1957 e5.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1222_CR21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.jaci.2016.11.029","volume":"139","author":"M Ballow","year":"2017","unstructured":"Ballow M, et al. Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). J Allergy Clin Immunol. 2017;139(6):2007-2010 e8.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01222-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T16:11:50Z","timestamp":1654272710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01222-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01222-8","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"10 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Immune Deficiency Foundation sponsored the mail surveys and submitted both survey protocols (IDF 2017 Patient Survey and the IDF 2018 Immunoglobulin Treatment Experiences and Preferences Surveys) for review by independent IRBs and each received exemption of oversight based on the Department of Health and Human Services regulations found at 45 CFR 46.101 (b)(2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"VHT is on the advisory board for CSL-Behring, Regeneron, and Takeda. VHT is a speaker and consultant for Takeda. CS is employed by the Immune Deficiency Foundation. DJR is recipient of research funding support from CSL-Behring. All other authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}